Lexaria Bioscience Corp. (LEXX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$2.79

From 52W high−87.06%

Volume43308.00

Market cap$5.48M

P/E (TTM)—

P/S (TTM)28.2x

Div yield—

Key dataOct 19, 2026

Open

$2.79

From 52W high

−87.06%

Volume

43308.00

Market cap

$5.48M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

33.2

MomentumView details →

1D Return

−9.09%

YTD Return

−73.19%

SummaryUpdated May 1, 2026

Lexaria Bioscience Corp. (NASDAQ:LEXX) is a Canadian biotechnology company founded in 2004 and headquartered in Kelowna, British Columbia. The company went public on NASDAQ in January 2021. Lexaria operates as a drug delivery technology company focused on developing and commercializing its proprietary DehydraTECH platform, which enhances the oral absorption of active pharmaceutical ingredients. The company maintains an in-house research laboratory and holds an intellectual property portfolio comprising 23 granted patents and approximately 50 pending patents worldwide.

Ask drillr about Lexaria Bioscience Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

8.0x

P/S (TTM)

28.2x

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−3985.58%

EBITDA Margin

−3948.18%

ROE (TTM)

−163.18%

ROA (TTM)

−161.71%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

−68.50%

EPS YoY

−46.53%

FCF YoY

+23.61%

Revenue CAGR 3Y

+40.34%

EPS CAGR 3Y

−40.43%

EBITDA YoY

+32.32%

MomentumView details →

1D Return

−9.09%

YTD Return

−73.19%

1Y Return

−82.47%

RSI (14)

33.2

vs 50D SMA

−60.55%

vs 200D SMA

−73.35%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

10.60x

Quick Ratio

10.60x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.08

EPS Surprise

−33.33%

Beats (12Q)

6/12

Next Q EPS Est

−$4.35

Avg Surprise (4Q)

17.89%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

194000.00

Net Income (TTM)

−7.73M

Op. CF (TTM)

−7.43M

Next earningsOct 28, 2026 →

Latest newsMore news →

Lexaria Bioscience Corp. completed an institutional financing that, together with an Australian tax refund, brought in a net $7.9 million.32d ago

Lexaria Bioscience Corp. announced definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, expecting gross proceeds of approximately $5.9 million, with closing expected on or about September 9, 2026.42d ago

Similar companies

Creative Medical Technology Holdings, Inc.CELZ Reviva Pharmaceuticals Holdings, Inc.RVPH Imunon, Inc.IMNN Moleculin Biotech, Inc.MBRX Traws Pharma, Inc.TRAW AlphaTON Capital Corp.ALP Find similar companies →

Latest newsMore news →

Lexaria Bioscience Corp. completed an institutional financing that, together with an Australian tax refund, brought in a net $7.9 million.32d ago Lexaria Bioscience Corp. announced definitive agreements for the immediate exercise of outstanding warrants to purchase 453,969 shares of common stock at a reduced exercise price of $12.92 per share, expecting gross proceeds of approximately $5.9 million, with closing expected on or about September 9, 2026.42d ago Lexaria Bioscience Corp. received a cash rebate of AUD$3,666,611.98 (USD$2.6 million) from the Australian Tax Office, deposited into the account of its wholly-owned subsidiary Lexaria (AU) Pty Ltd.49d ago